FDA Grants Accelerated Approval to Lynozyfic for Relapsed or Refractory Multiple Myeloma

The FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron), a bispecific B-cell maturation ...

JULY 2, 2025